3.86

0.52% -0.02

After Hours: 3.86

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $3.86, with a volume of 3.05M. It is down -0.52% in the last 24 hours and up +8.43% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Previous Close:

$3.88

Open:

$3.92

24h Volume:

3.05M

Relative Volume:

0.65

Market Cap:

$1.01B

Revenue:

$194.75M

Net Income/Loss:

$-51.26M

P/E Ratio:

-13.79

EPS:

-0.28

Net Cash Flow:

$-23.38M

1W Performance:

-1.78%

1M Performance:

+8.43%

6M Performance:

+86.47%

1Y Performance:

+183.82%

1-Day Range:

$3.83

$3.97

1-Week Range:

$3.81

$4.00

52-Week Range:

$1.07

$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1163)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

181

Twitter

@akebiatx

Next Earnings Date

2024-11-07

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	3.86	1.03B	194.75M	-51.26M	-23.38M	-0.28
ZTS Zoetis Inc	148.60	68.99B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.43	46.36B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.60	44.74B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.06	18.81B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	292.01	13.33B	2.99B	1.21B	1.13B	25.06

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Resumed	H.C. Wainwright	Buy
Apr-28-25	Initiated	Leerink Partners	Outperform
Apr-01-25	Initiated	Jefferies	Buy
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

09:23 AM

What analysts say about Akebia Therapeutics Inc. stockStrongest growth potential - Jammu Links News

09:23 AM

01:24 AM